Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 30;2(8):luae131. doi: 10.1210/jcemcr/luae131

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms.

PMC Copyright notice

Figure 3. — Pre-and 6 months posttreatment MRI of the same patient. Axial T2W STIR (A), T1-opposed phase (B), and contrast-enhanced T1W SPIR (C) images on pretreatment MRI demonstrate a heterogeneous left adrenal mass (arrow in A and B) with intense contrast enhancement (arrow in C). A hepatic metastasis is also seen in the right liver lobe (arrowheads in A-C). Corresponding posttreatment MRI exhibits a significant decrease in the adrenal lesion size (arrows in D-F). Note the minimal enhancement of the lesion on the postcontrast image (arrow in F), another finding indicative of the tumor's response to treatment. Liver lesion is also decreased (arrowheads in D and E) and less enhanced (arrowhead in F) on posttreatment MRI.

Abbreviations: MRI, magnetic resonance imaging.